OPNT - OPNT STOCK NEWS

Opiant Pharmaceuticals (NASDAQ: OPNT) has granted stock options and restricted stock units to two new employees, including Matthew Ruth, the new Chief Commercial Officer. The Compensation Committee approved 50,000 stock options and 15,000 restricted stock units for Ruth, with an exercise price of $16.41 per share. Additionally, another employee received 6,500 stock options and 3,200 restricted stock units. The vesting period for these awards is four years, with 25% vesting annually, contingent on continued employment.

Opiant Pharmaceuticals has appointed Matthew Ruth as Chief Commercial Officer, effective July 12, 2021. Ruth brings extensive commercial experience, having led the successful launch of the FDA-approved nasal naloxone spray for opioid overdose. At Opiant, he will focus on advancing OPNT003, a new nasal nalmefene treatment for overdose, especially against synthetic opioids like fentanyl. Dr. Roger Crystal, President and CEO, expressed confidence in Ruth's leadership to strengthen Opiant’s capabilities in tackling addiction and overdose issues.

Opiant Pharmaceuticals (NASDAQ: OPNT) announced positive results from a confirmatory pharmacokinetic (PK) study for its nasal nalmefene product, OPNT003, aimed at treating opioid overdose. The study involved 68 healthy subjects and showed that OPNT003 achieved significantly higher plasma concentrations compared to a 1 mg intramuscular nalmefene injection (p<0.0001). The results align with previous pilot study findings. The company anticipates pharmacodynamic (PD) study results later this year, which will support a New Drug Application submission before early 2022.

Opiant Pharmaceuticals, Inc. (NASDAQ: OPNT) announced that CEO Dr. Roger Crystal will present at the Jefferies Virtual Healthcare Conference on June 3, 2021, from 3:30-3:55 PM ET. The conference will include 1x1 investor meetings, and a live webcast of the presentation will be accessible on Opiant’s website in the Investors section. A replay of the webcast will be available for 30 days post-event. Opiant specializes in developing medications for addictions and drug overdoses, prominently known for NARCAN® Nasal Spray.

Opiant Pharmaceuticals (NASDAQ: OPNT) announced its 2021 Annual Meeting of Shareholders will be held virtually due to COVID-19 concerns. The meeting is scheduled for June 15, 2021, at 9:00 a.m. PDT, remaining unchanged in agenda. Shareholders can participate via live audio webcast. Those eligible must have their 16-digit control number to vote electronically. The company encourages all shareholders to submit their proxies in advance. The proxy statement detailing business matters for the meeting is available online.

Opiant Pharmaceuticals (NASDAQ: OPNT) reported Q1 2021 revenues of $6.4 million, a rise from $4.3 million in Q1 2020. The increase stems from royalties from NARCAN® Nasal Spray, with sales reported by Emergent BioSolutions at $74.2 million. The company is advancing its pipeline, including OPNT003 for opioid overdose, with key data anticipated in Q3 and Q4. As of March 31, 2021, Opiant holds $50.6 million in cash. Despite a net loss of $2.8 million for Q1 2021, the financial outlook remains strong, with expected royalty revenues of $27.8 million from NARCAN® for the full year.

Opiant Pharmaceuticals, Inc. (NASDAQ: OPNT) will release its financial results for Q1 2021 on May 11, 2021, after market close. A conference call will follow at 4:30 PM ET the same day. Investors can join by dialing 877-407-0792 (U.S.) or 201-689-8263 (International) with the conference ID 13718590. The webcast will be available on the company's investor website.

Opiant is known for developing NARCAN® Nasal Spray and is focusing on creating new treatments for drug overdose and addiction.

Opiant Pharmaceuticals (NASDAQ: OPNT) has initiated a pharmacodynamic study comparing its nasal nalmefene (OPNT003) with nasal naloxone for reversing remifentanil-induced respiratory depression. This randomized clinical trial is timely, as opioid overdose deaths have surged, reaching over 63,000 in 2020. Top-line data from the study is anticipated in Q4 2021. Notably, nalmefene is reported to be five times more potent than naloxone, with a longer half-life, offering potential advantages in treating overdoses. The trial's goal is to support OPNT003's therapeutic benefits amid rising opioid overdose incidents.

Opiant Pharmaceuticals (NASDAQ: OPNT) announces the receipt of $1.8 million as the final tranche of a $7.4 million grant from the National Institute on Drug Abuse (NIDA) for the development of OPNT003, a nasal nalmefene intended for opioid overdose treatment. This funding comes amid rising overdose deaths, particularly from synthetic opioids like fentanyl. CEO Roger Crystal highlighted the grant's validation of their progress towards FDA submission for OPNT003, which they believe can significantly address the opioid crisis. Opiant's efforts are also backed by a contract with the Biological Advance Research and Development Agency.